Amalgamated Bank raised its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN – Free Report) by 29.6% in the second quarter, Holdings Channel.com reports. The firm owned 2,223 shares of the company’s stock after purchasing an additional 508 shares during the period. Amalgamated Bank’s holdings in Arvinas were worth $59,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the business. RTW Investments LP purchased a new stake in shares of Arvinas during the 4th quarter valued at about $173,427,000. Vanguard Group Inc. increased its holdings in shares of Arvinas by 29.9% in the 1st quarter. Vanguard Group Inc. now owns 6,299,556 shares of the company’s stock worth $260,046,000 after buying an additional 1,448,166 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Arvinas by 42.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,832,123 shares of the company’s stock worth $157,731,000 after buying an additional 1,143,452 shares during the last quarter. Commodore Capital LP bought a new position in Arvinas during the fourth quarter valued at $41,160,000. Finally, Boxer Capital LLC bought a new position in shares of Arvinas during the fourth quarter valued at approximately $25,051,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.
Arvinas Trading Up 1.0 %
ARVN opened at $24.88 on Wednesday. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of -4.20 and a beta of 1.97. The company has a fifty day simple moving average of $25.63 and a 200 day simple moving average of $29.96. Arvinas, Inc. has a twelve month low of $13.57 and a twelve month high of $53.08.
Wall Street Analyst Weigh In
ARVN has been the subject of several recent research reports. Oppenheimer reduced their target price on shares of Arvinas from $70.00 to $50.00 and set an “outperform” rating for the company in a report on Wednesday, July 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of Arvinas in a research report on Monday, September 9th. HC Wainwright reiterated a “buy” rating and set a $87.00 price target on shares of Arvinas in a report on Thursday, August 1st. Barclays lowered their price target on Arvinas from $60.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. Finally, Wedbush reiterated an “outperform” rating and issued a $57.00 price objective on shares of Arvinas in a research report on Tuesday, July 30th. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.
View Our Latest Analysis on Arvinas
About Arvinas
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
See Also
- Five stocks we like better than Arvinas
- What is the Dogs of the Dow Strategy? Overview and Examples
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Ride Out The Recession With These Dividend KingsĀ
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Want to see what other hedge funds are holding ARVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arvinas, Inc. (NASDAQ:ARVN – Free Report).
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.